Scarica l'app Stockscreener
106.92
5.08%
-5.72
Precedente Chiudi:
$112.64
Aprire:
$113.06
Volume 24 ore:
1.05M
Relative Volume:
1.11
Capitalizzazione di mercato:
$5.84B
Reddito:
$1.34M
Utile/perdita netta:
$-173.66M
Rapporto P/E:
-25.84
EPS:
-4.1385
Flusso di cassa netto:
$-130.49M
1 W Prestazione:
+2.94%
1M Prestazione:
+9.68%
6M Prestazione:
+100.26%
1 anno Prestazione:
+417.27%
Intervallo 1D:
$105.66
$114.55
Intervallo di 1 settimana:
$100.00
$114.55
Portata 52W:
$18.08
$114.55
Dianthus Therapeutics Inc Stock (DNTH) Company Profile
Nome
Dianthus Therapeutics Inc
Settore
Industria
Telefono
929-999-4055
Indirizzo
7 TIMES SQUARE, NEW YORK
Compare DNTH vs VRTX, REGN, ARGX, RVMD, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DNTH
Dianthus Therapeutics Inc
|
106.92 | 5.71B | 1.34M | -173.66M | -130.49M | -4.1385 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Dianthus Therapeutics Inc Stock (DNTH) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-09 | Iniziato | Wolfe Research | Outperform |
| 2026-03-10 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2025-10-14 | Iniziato | Truist | Buy |
| 2025-07-02 | Iniziato | William Blair | Outperform |
| 2024-12-20 | Iniziato | TD Cowen | Buy |
| 2024-10-03 | Iniziato | Oppenheimer | Outperform |
| 2024-07-26 | Iniziato | Robert W. Baird | Outperform |
| 2024-06-27 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-05-16 | Iniziato | H.C. Wainwright | Buy |
| 2024-02-15 | Iniziato | Stifel | Buy |
| 2023-12-26 | Iniziato | Jefferies | Buy |
| 2023-11-22 | Iniziato | Wedbush | Outperform |
| 2023-10-30 | Iniziato | Guggenheim | Buy |
| 2023-09-28 | Iniziato | Raymond James | Outperform |
| 2022-08-25 | Downgrade | Goldman | Buy → Neutral |
| 2022-01-06 | Aggiornamento | Goldman | Neutral → Buy |
| 2021-08-20 | Ripresa | Goldman | Neutral |
| 2021-08-03 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-07-22 | Reiterato | B. Riley Securities | Buy |
| 2021-06-29 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-06-15 | Iniziato | BTIG Research | Buy |
| 2021-05-18 | Iniziato | B. Riley Securities | Buy |
| 2021-01-07 | Iniziato | Mizuho | Buy |
| 2020-06-08 | Aggiornamento | Goldman | Neutral → Buy |
| 2019-03-25 | Downgrade | Goldman | Buy → Neutral |
| 2019-03-15 | Iniziato | Raymond James | Outperform |
Mostra tutto
Dianthus Therapeutics Inc Borsa (DNTH) Ultime notizie
Dianthus Therapeutics, Inc. $DNTH Shares Bought by SummitTX Capital L.P. - MarketBeat
Octagon Capital Advisors LP Has $163.36 Million Position in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Dianthus Therapeutics Inc (DNTH) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Dianthus Therapeutics Inc (DNTH) Cash Flow - TradingKey
Dianthus Therapeutics Inc (DNTH) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Dianthus Therapeutics, Inc. Revenue Breakdown – NASDAQ:DNTH - TradingView
Dianthus Therapeutics, Inc. Revenue Breakdown – BOATS:DNTH - TradingView
Spruce Street Capital LP Raises Stock Holdings in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
DNTH|Dianthus Therapeutics Inc|Price:103.870|Chg%:-0.920 - TradingKey
Walleye Capital LLC Has $12.89 Million Position in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Jennison Associates LLC Buys New Position in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Sets New 52-Week HighTime to Buy? - MarketBeat
Dianthus Therapeutics Inc. Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Operational DisciplineProfit Announcement - dars.gov.et
Wedbush Maintains Dianthus Therapeutics (DNTH) Outperform Recommendation - MSN
Dianthus Therapeutics Stock Surges After Initiating Major Phase 3 Clinical Trial - TIKR.com
Enterprise value to EBITDA forward of Dianthus Therapeutics, Inc. – FWB:87E - TradingView
Dianthus Therapeutics, Inc. (DNTH) reports Q1 loss, lags revenue estimates - MSN
Dianthus Therapeutics DNTH Jumps As Phase 3 EMERGE Trial Kicks Off - timothysykes.com
DNTH Stock Pops As Phase 3 EMERGE Trial Kicks Off - StocksToTrade
Dianthus Therapeutics stock hits 52-week high at 102.38 USD By Investing.com - Investing.com Nigeria
Dianthus Therapeutics stock hits 52-week high at 102.38 USD - Investing.com India
Dianthus Therapeutics Rockets As Phase 3 Hype Builds - TipRanks
Form 4 Dianthus Therapeutics Inc For: 13 July By Investing.com - Investing.com Nigeria
Dianthus therapeutics CFO Ryan Savitz sells $3.16 million in shares By Investing.com - Investing.com Australia
Dianthus therapeutics CFO Ryan Savitz sells $3.16 million in shares - Investing.com
Dianthus Therapeutics (DNTH) CFO sells 31,249 shares in 10b5-1 trades - Stock Titan
Dianthus Therapeutics (DNTH) Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive SentimentMid-Term Outlook - Bölüm Sonu Canavarı
Dianthus Therapeutics (DNTH) Starts Phase 3 EMERGE Trial, Is The Upside Already Priced In? - Sahm
Form 144 Dianthus Therapeutics For: 9 July By Investing.com - Investing.com South Africa
[144] Dianthus Therapeutics, Inc. /DE/ SEC Filing - Stock Titan
Dianthus Therapeutics stock hits 52-week high at 99.36 USD By Investing.com - Investing.com Nigeria
Dianthus Therapeutics stock hits 52-week high at 99.36 USD - Investing.com
Dianthus Advances Claseprubart Into Phase 3 EMERGE Trial, Raising Stakes in the Myasthenia Gravis Market - TipRanks
Price to earnings forward of Dianthus Therapeutics, Inc. – MUN:87E - TradingView
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Enterprise value to revenue forward of Dianthus Therapeutics, Inc. – NASDAQ:DNTH - TradingView
DNTHDianthus Therapeutics Inc Revenue Breakdown - Finviz
Dianthus Therapeutics Inc. Q1 2026 Earnings: EPS Surprise of 22.28% Drives Positive Stock ReactionRevenue Per Share - dars.gov.et
DNTH News | DIANTHUS THERAPEUTICS INC (NASDAQ:DNTH) - ChartMill
Dianthus Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(C)(4) - The Manila Times
Cartesian Therapeutics Announces New Employment Inducement Grants - Yahoo Finance
Price to book forward of Dianthus Therapeutics, Inc. – NASDAQ:DNTH - TradingView
DNTH Stock Soars After Early ‘Go’ Decision For Drug In Autoimmune Disorder Program, Boosting Wall Street Optimism For Potential Launch - Stocktwits
Why Dianthus Therapeutics (DNTH) Is Up 11.4% After Launching Its Phase 3 EMERGE gMG Trial - Sahm
Dianthus Therapeutics stock hits 52-week high at 96.85 USD By Investing.com - Investing.com South Africa
Dianthus Therapeutics, Inc.(NasdaqCM:DNTH) dropped from Russell Microcap Value Benchmark Index - marketscreener.com
Dianthus Therapeutics, Inc.(NasdaqCM:DNTH) dropped from Russell 2000 Value Benchmark - marketscreener.com
Dianthus Therapeutics Inc Azioni (DNTH) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Dianthus Therapeutics Inc Azioni (DNTH) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Savitz Ryan | EVP, CFO & CBO |
Jul 09 '26 |
Sale |
101.03 |
31,249 |
3,157,151 |
0 |
2.44%
0.02%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):